Patent · US Active

Enhanced antisense oligonucleotides

US7919472B2 · kind B2 · utility

32Cited by

6References

20Claims

0Family size

Assignee

Isis Pharmaceuticals, Inc. · US

Inventors

Brett P. Monia · Carlsbad, US
Andrew M. Siwkowski · Carlsbad, US
Sanjay Bhanot · Carlsbad, US

Key dates

Filing date	Sep 19, 2005
Grant date	Apr 5, 2011
Priority date	—
Expiry date	Jun 9, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened antisense oligonucleotides.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.